Nascent Biotech, Inc. (NBIO)

Nascent Biotech Cash Flow Statement

Financials in millions USD. Fiscal year is April - March.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2024	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Net Income	-1.92	-2.09	-2.8	-0.47	-0.96	-4
Other Amortization	0.15	0.38	1.34	0.33	0.07	0.06
Stock-Based Compensation	0.82	0.88	0.76	0.12	0.79	1.1
Other Operating Activities	-0.31	-0.52	-0.77	-0.47	-0.78	0.47
Change in Accounts Receivable	-	-	-	0.75	-0.75	-
Change in Accounts Payable	0.04	0.26	-0.25	0.17	0.23	0.33
Change in Other Net Operating Assets	-0.11	-0.1	-0.07	-0.01	0.42	1.49
Operating Cash Flow	-1.35	-1.19	-1.79	0.41	-0.99	-0.55
Short-Term Debt Issued	-	0.23	1.93	0.2	0.35	0.2
Total Debt Issued	0.23	0.23	1.93	0.2	0.35	0.2
Short-Term Debt Repaid	-	-0.4	-0.28	-0.52	-	-
Total Debt Repaid	-0.4	-0.4	-0.28	-0.52	-	-
Net Debt Issued (Repaid)	-0.18	-0.18	1.66	-0.32	0.35	0.2
Issuance of Common Stock	1.56	1.56	0.21	-	-	0.12
Financing Cash Flow	1.39	1.39	1.87	-0.32	0.99	0.43
Miscellaneous Cash Flow Adjustments	-	-	-	-	-	-0
Net Cash Flow	0.04	0.2	0.08	0.09	-0	-0.13
Cash Interest Paid	-	-	0.01	0.03	-	-
Levered Free Cash Flow	-0.83	-0.95	-0.01	0.4	-2.66	1.08
Unlevered Free Cash Flow	-0.88	-1.08	-0.28	0.28	-2.52	1.08
Change in Net Working Capital	0.38	0.57	-0.31	-0.45	2.43	-2.13

Updated Aug 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.